The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 17, 2023
Filed:
Jan. 28, 2019
Applicant:
University of Pittsburgh—of the Commonwealth System of Higher Education, Pittsburgh, PA (US);
Inventors:
Greg M. Delgoffe, Pittsburgh, PA (US);
Dayana Rivadeneira, Pittsburgh, PA (US);
Padmavathi Sampath, Pittsburgh, PA (US);
Stephen H. Thorne, Pittsburgh, PA (US);
Assignee:
University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 35/763 (2015.01); A61P 35/00 (2006.01); A61K 35/768 (2015.01); C07K 14/495 (2006.01); C07K 14/54 (2006.01); C07K 14/545 (2006.01); C07K 14/55 (2006.01); C07K 14/56 (2006.01); C07K 14/57 (2006.01); C07K 14/575 (2006.01); C12N 7/00 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 35/763 (2013.01); A61K 35/768 (2013.01); A61P 35/00 (2018.01); C07K 14/495 (2013.01); C07K 14/545 (2013.01); C07K 14/5406 (2013.01); C07K 14/5418 (2013.01); C07K 14/5425 (2013.01); C07K 14/5428 (2013.01); C07K 14/5437 (2013.01); C07K 14/5443 (2013.01); C07K 14/55 (2013.01); C07K 14/56 (2013.01); C07K 14/57 (2013.01); C07K 14/5759 (2013.01); C12N 7/00 (2013.01); A61K 45/06 (2013.01);
Abstract
Recombinant oncolytic viruses (OVs) that express one or more metabolic modulator proteins, such as an adipokine (e.g., leptin or chemerin), insulin, and/or IGF-1, and methods of their use to treat cancer, for example in immunotherapy anti-cancer treatments. In some examples, such recombinant OVs and methods increase T cell infiltration into the tumor or tumor microenvironment.